N@N

Radient Pharmaceuticals to Present Onko-Sure(TM) Cancer Test at Prestigious ASCO Annual Oncology Conference

_{//health-fitness.news-articles.net/content/2010/ .. prestigious-asco-annual-oncology-conference.html}
^{Published in Health and Fitness on Thursday, June 3rd 2010 at 6:10 GMT by Market Wire}  

TUSTIN, CA--(Marketwire - June 3, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: [ RPC ]) announced today it is attending and presenting at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago June 4-8, 2010.

ASCO is the world's leading professional organization representing physicians who care for people with cancer. With more than 27,000 oncology practitioners as members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. More than 30,000 cancer specialists from around the world are expected to gather at the meeting to discuss the latest innovations in cancer research, product and testing quality, practice and technology.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, "RPC is excited to be an active participant at ASCO, an event that represents the largest gathering of physicians, scientists and oncology experts. This year's event serves as an ideal venue for RPC to share its latest scientific and product developments, company progress and market developments."

In addition to Douglas MacLellan, RPC's Director of Oncology, Dr. Motamed-Khorasani and Christopher Gee, Director of International Sales and Marketing will be on hand at Booth 13148, to speak with event attendees about RPC's proprietary Onko-Sure™ in vitro diagnostic (IVD) cancer test and the Company's worldwide commercialization strategy.

Those interested in pre-scheduling a meeting with RPC at ASCO may contact [ cgee@radient-pharma.com ] or call 310-562-6783. Additional information regarding RPC's Onko-Sure IVD cancer test is available at [ www.radient-pharma.com ]. Radient Pharmaceuticals' subsidiary AMDL Diagnostics Inc. will provide additional updates regarding their participation at ASCO via its corporate website at [ www.radient-pharma.com ].

Onko-Sure™ is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products. Visit [ www.Radient-Pharma.com ] for additional information.

About ASCO
ASCO is the world's leading professional organization representing physicians who care for people with cancer. With more than 27,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. For ASCO information and resources, visit [ www.asco.org/presscenter ]. Patient-oriented cancer information is available at [ www.cancer.net ].

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.